- Current report filing (8-K)
09 August 2011 - 6:39AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
August 8, 2011
AspenBio Pharma, Inc.
(Exact name of Registrant as specified in its charter)
Colorado
|
|
001-33675
|
|
84-155338
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
1585 South Perry Street
Castle Rock, Colorado
|
|
80104
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code (303) 794-2000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
The power point presentation information furnished on Exhibit 99.1 is hereby incorporated by reference under this Item 7.01 as if fully set forth herein and is available on the Company’s website. The presentation will be used for the first time at the CANACCORD/Genuity 31
st
Annual Growth Conference on August 9, 2011.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibits
99.1
|
AspenBio Pharma — “Power Point Presentation” dated August 8, 2011
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized
|
|
|
|
|
|
|
|
|
|
AspenBio Pharma, Inc.
(Registrant)
|
|
Date:
August 8, 2011
|
By:
|
/s/ Jeffrey G. McGonegal
|
|
|
|
Name: Jeffrey G. McGonegal
|
|
|
|
Title: Chief Financial Officer
|
|
|
Aspenbio Pharma, Inc. (MM) (NASDAQ:APPYD)
Historical Stock Chart
From May 2024 to Jun 2024
Aspenbio Pharma, Inc. (MM) (NASDAQ:APPYD)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Aspenbio Pharma, Inc. (MM) (NASDAQ): 0 recent articles
More News Articles